<SEC-DOCUMENT>0001104659-23-104776.txt : 20230928
<SEC-HEADER>0001104659-23-104776.hdr.sgml : 20230928
<ACCEPTANCE-DATETIME>20230928163035
ACCESSION NUMBER:		0001104659-23-104776
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230928
FILED AS OF DATE:		20230928
DATE AS OF CHANGE:		20230928

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		231290169

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2327144d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K<BR>
<BR>
</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN PRIVATE
ISSUER</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>PURSUANT TO RULE 13a-16
OR 15d-16 OF THE </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>SECURITIES EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of September 2023</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39446</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Exact Name of Registrant as Specified in Its
Charter</I>)</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive office)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 20-F</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 14%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">X</P></TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 40-F</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 14%">
</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 12, 2023, CureVac N.V. (the &ldquo;Company&rdquo;) issued
a press release reporting progress in its intellectual property infringement case against BioNTech in Germany.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information included in this Form 6-K (including Exhibit 99.1,
but excluding the statements of the Company&rsquo;s Chief Executive Officer contained in Exhibit 99.1 hereto) is hereby incorporated by
reference into the Company&rsquo;s Registration Statement on Form F-3 (File No. 333-259613).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 50%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 25%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;Alexander Zehnder</FONT></TD>
    <TD STYLE="vertical-align: top; width: 23%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: September 28, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 86px; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="width: 10px">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center"><A HREF="tm2327144d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm2327144d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CureVac N.V. Press Release dated September 28, 2023.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2327144d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="tm2327144d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac Reports Progress in Intellectual Property
Infringement Case<BR>
Against BioNTech in Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Regional Court D&uuml;sseldorf postpones infringement ruling on four intellectual
property rights in lawsuit filed by CureVac against BioNTech</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ruling on infringement to be provided latest once the validity of the intellectual
property rights in suit has been determined by the relevant patent offices expected<BR>
in 2024</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">As German infringement courts only suspend the proceedings if an intellectual
property right is infringed and its validity has been challenged, it may be concluded that the Regional Court D&uuml;sseldorf found all
four intellectual property rights to be infringed</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ruling on infringement of a fifth intellectual property right scheduled for
December 28, 2023</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>T&Uuml;BINGEN, Germany
/ BOSTON, USA &ndash; September 28, 2023 &ndash; </B>CureVac N.V. (Nasdaq: CVAC) (&ldquo;CureVac&rdquo;), a global biopharmaceutical company
developing a new class of transformative medicines based on messenger ribonucleic acid (&ldquo;mRNA&rdquo;), today announced that the
Regional Court D&uuml;sseldorf has decided to suspend proceedings on four intellectual property rights in the infringement lawsuit filed
by CureVac against BioNTech. A ruling on infringement will be provided latest once the validity of the intellectual property rights has
been determined by the relevant patent offices. The validity of these intellectual property rights has been challenged by BioNTech. Under
German law, patent infringement and validity lawsuits are adjudicated in separate proceedings. Normally, German infringement courts only
suspend the proceedings if the validity of the intellectual property has been challenged and is also considered infringed. Therefore,
it may be concluded that the Regional Court D&uuml;sseldorf found all four intellectual property rights to be infringed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&ldquo;Given the particularities
of German patent law, where patent infringement and validity are adjudicated by separate proceedings, the suspension of proceedings until
the validity of intellectual property rights has been determined was expected&rdquo; said Dr. Alexander Zehnder, Chief Executive Officer
of CureVac. &ldquo;We are confident in the strength of our intellectual property portfolio and today&rsquo;s decision indicates that the
intellectual property rights at issue are infringed.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac filed a patent infringement lawsuit in
Germany against BioNTech in early June 2022. The decision today was made following an oral hearing on August 15, 2023, before the Regional
Court D&uuml;sseldorf, which covered five intellectual property rights. A ruling on infringement on the fifth intellectual property right
(EP1857122B1) is scheduled for December 28, 2023. A preliminary opinion on this intellectual property right issued in April 2023 by the
German Federal Patent Court supported its validity. A first ruling on validity of this intellectual property right is scheduled for December
19, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2327144d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Three additional intellectual property rights,
added to the infringement lawsuit in July 2023, were not covered in the oral hearing. These are expected to be addressed in 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the U.S., Pfizer/BioNTech filed a lawsuit
against CureVac in July 2022, asking for confirmation that Comirnaty&reg; does not infringe three CureVac patents. These patents are
included among the ten U.S. patents referenced by CureVac&rsquo;s counterclaim: 11,135,312; 11,149,278; 11,286,492; 11,345,920;
10,760,070; 11,241,493; 11,471,525; 11,576,966; 11,596,686 and 11,667,910 CureVac is represented in the U.S. by Mark H. Izraelewicz
from Marshall, Gerstein &amp; Borun LLP and represented in Germany by Oliver Jan J&uuml;ngst from Bird &amp; Bird and Andreas Graf
von Stosch from Graf von Stosch Patentanwaltsgesellschaft.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac (Nasdaq: CVAC) is a global biopharmaceutical
company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing
this versatile biological molecule for medical purposes. The principle of CureVac&rsquo;s proprietary technology is the use of optimized
mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July
2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based
on CureVac&rsquo;s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19
vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline
across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has
its headquarters in T&uuml;bingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium,
Switzerland and the U.S. Further information can be found at <U>www.curevac.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; background-color: white"><B>CureVac
Media and Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; text-align: justify; background-color: white">Dr. Sarah
Fakih, Vice President Corporate Communications and Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">CureVac, T&uuml;bingen,
Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">T: +49 7071
9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">M: +49 160
90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>sarah.fakih@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><IMG SRC="tm2327144d1_ex99-1img001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains statements that constitute
 &ldquo;forward looking statements&rdquo; as that term is defined in the United States Private Securities Litigation Reform Act of 1995,
including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or
its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH,
CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the &ldquo;company&rdquo;) regarding future events or future
results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company&rsquo;s
vaccine and treatment candidates and the company&rsquo;s strategies, financing plans, growth opportunities and market growth. In some
cases, you can identify such forward-looking statements by terminology such as &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;project,&rdquo; or &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
 &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo; &ldquo;intend,&rdquo; or &ldquo;should,&rdquo; the negative of these
terms or similar expressions. Forward-looking statements are based on management&rsquo;s current beliefs and assumptions and on information
currently available to the company. However, these forward-looking statements are not a guarantee of the company&rsquo;s performance,
and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other
variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial
markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense
and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability
to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from
increasing competition and consolidation in the company&rsquo;s industry, the effects of the COVID-19 pandemic on the company&rsquo;s
business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection,
ability to provide for patient safety and fluctuations of operating results due to the effect of exchange rates or other factors. Such
risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements.
Many of these risks are outside of the company&rsquo;s control and could cause its actual results to differ materially from those it thought
would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake,
and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such
statements to reflect future events or developments, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For further information, please reference the
company&rsquo;s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting
EDGAR on the SEC website at <U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2327144d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2327144d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ *T# 2(  A$! Q$!_\0
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9D^H2R7DI5,A%WS,S!5!. #CDUU=% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
